Latest New Zealand News

DGL Group reported a modest revenue rise but faced a significant earnings dip in FY25, driven by losses in its Environmental division and restructuring costs. The company is now focusing on integration and operational efficiencies to rebound in FY26.

MedAdvisor reported a 36% revenue drop in FY25, driven by US health program setbacks, and sold its ANZ business to focus on restructuring its US operations.

Bathurst Resources reports a dip in FY25 earnings due to lower coal prices and operational challenges but pushes forward with key development projects Buller and Tenas, targeting production growth from FY29.

Harvey Norman Holdings reported a robust 39% jump in profit before tax for FY25, driven by strong franchise sales, a booming property portfolio, and strategic international expansion.

Amaero Ltd has launched a $3 million Share Purchase Plan offering eligible shareholders in Australia and New Zealand the chance to buy new shares at $0.40 each, matching a recent placement price. The offer opens on 29 August and closes on 19 September 2025.

Cluey Ltd has marked a pivotal year with a $4.4 million EBITDA improvement and its first positive operating cash flow quarter, alongside renewed student growth. The company is now pivoting towards AI-driven product expansion to sustain momentum.

Gratifii Limited has reported a robust FY25 with revenue and transaction values more than doubling, driven by key acquisitions and new product launches. The company is poised for further growth in FY26 with platform upgrades and expanding client partnerships.

Dusk Group Limited reported solid financial growth for FY25, with revenue up 7.8% and net profit rising 5.5%, underpinned by strong online sales and strategic store expansions.

Lynas Rare Earths has successfully completed a A$750 million institutional placement, strengthening its balance sheet to fund ambitious growth plans under its Towards 2030 strategy.

Novatti Group reports a record $51.8 million revenue for FY25 alongside a 65% improvement in underlying EBITDA, signaling a successful turnaround and a strategic pivot back to growth.

PYC Therapeutics has reported promising safety data from the initial phase of its clinical trial for PYC-003, an RNA therapy targeting the root cause of Polycystic Kidney Disease. The findings, presented at the ANZSN conference, highlight the drug’s tolerability in healthy volunteers, paving the way for further clinical development.

Memphasys Limited reported a net loss of AUD 4.94 million for FY25 while accelerating commercial efforts for its Felix System and advancing its RoXsta diagnostics platform.